PMID: 24445818 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 20, 2014 Category: Cancer & Oncology Authors: L'allemain G, Vignot S, Massard C, Bay JO Tags: Bull Cancer Source Type: research
Melanomas of the female genital tract: state of the art.
The objective of this review is to describe and report the current state of knowledge about gynaecologic melanomas. PMID: 24445910 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 20, 2014 Category: Cancer & Oncology Authors: Trone JC, Guy JB, Mery B, Langrand Escure J, Lahmar R, Moncharmont C, Rivoirard R, Semay T, Chauleur C, Collard O, Vignot S, Magné N Tags: Bull Cancer Source Type: research
Loco-regional treatments of the metastatic sites for patients with pauci-metastatic cutaneous melanoma (without brain metastasis): French national guidelines.
, Leccia MT Abstract the last years are marked by the emergence of new molecules for the treatment of metastatic cutaneous melanoma with a significant benefit on the survival. Besides, some techniques are in development for the loco-regional treatment of the metastatic sites, bringing new therapeutic perspectives. However, their respective use and place in the therapeutic strategy are debated by healthcare professionals. the French National Cancer Institute leads a national clinical practice guidelines project since 2008. It realized a review of these modalities of treatment and developed recommendations. the clin...
Source: Bulletin du Cancer - December 26, 2013 Category: Cancer & Oncology Authors: Sassolas B, Mourrégot A, Thariat J, Tiffet O, Dygai-Cochet I, Mirabel X, Truc G, Cupissol D, Modiano P, Combemale P, Bedane C, Derrey S, Lamant L, Lubrano V, Siegrist S, Rougé-Bugat ME, Mazeau-Woynar V, Verdoni L, Planchamp F, Leccia MT Tags: Bull Cancer Source Type: research
Immunotherapies and targeted therapies in medical oncology.
Abstract New immunotherapies, also called "immune checkpoints", are promising and showed interesting antitumoral activities in particular in advanced setting of melanoma, clear cell renal cancer or non-small cell lung carcinoma. These treatments include ipilimumab, anti-PD-1 and anti-PD-L1. There is a strong rational for combination of immunotherapies and targeted therapies. This review is dedicated to expose the theorical issues and preclinical data of such combinations. This review examined the impact of immunotherapies on transduction pathways and modification of immunity related to targeted therapies...
Source: Bulletin du Cancer - December 12, 2013 Category: Cancer & Oncology Authors: Rousseau B, Champiat S, Loirat D, Arrondeau J, Lemoine N, Soria JC Tags: Bull Cancer Source Type: research
Breast cancer and axillary area: state of the art and perspectives.
Abstract A therapeutic surgical de-escalation has been observed since many years with an actual prolongation for axillary lymph node area treatment. Axillary lymph node dissection (ALND) omission has been studied before and after validation of sentinel node (SN) biopsy procedure. A non-inferiority of ALND omission has been reported in case of non-involved SN. ALND omission has been studied in case of SN involvement without consensus in relation with scientific level of proof and with selective indications. The purpose of this work is to make a synthesis of the experiences on this subject then to envisage the curre...
Source: Bulletin du Cancer - December 6, 2013 Category: Cancer & Oncology Authors: Houvenaeghel G, Cohen M, Chereau Ewald E, Bannier M, Buttarelli M, Jauffret C, Lambaudie E Tags: Bull Cancer Source Type: research
Treatment of testicular cancer.
ard C Abstract Germ-cell tumours (GCTs) are the most common type of cancer in young men. Since the late 1970s, disseminated GCT have been a paradigm for curable metastatic cancer and metastatic GCTs are highly curable with cisplatin-based chemotherapy followed by surgical resection of residual masses. Patients' prognosis is currently assessed using the International Germ-Cell Consensus Classification (IGCCC) and used to adapt the burden of chemotherapy. Approximately 20% of patients still do not achieve cure after first-line cisplatin-based chemotherapy, and need salvage chemotherapy (high dose or standard dose ch...
Source: Bulletin du Cancer - December 6, 2013 Category: Cancer & Oncology Authors: Droz JP, Boyle H, Culine S, Fizazi K, Fléchon A, Massard C Tags: Bull Cancer Source Type: research
Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 Patients.
Abstract The combination of paclitaxel and bevacizumab was EMA-approved as first-line therapy in metastatic breast cancer. Moreover, in vitro studies showed a potential antiangiogenic synergistic effect of paclitaxel and bevacizumab. Between November 2008 and March 2010, this case series study included 15 patients with metastatic non squamous-cell lung carcinoma (NSCLC). Those were bevacizumab eligible and received the same regimen used in metastatic breast cancer with weekly paclitaxel (80 mg/m(2), days 1, 8 and 15) and bevacizumab (10 mg/kg at days 1 and 15) after at least one prior line of chemoth...
Source: Bulletin du Cancer - December 6, 2013 Category: Cancer & Oncology Authors: Le Moulec S, Hadoux J, Gontier E, Chargari C, Helissey C, Lamand V, Tanz R, Farace F, Vedrine L, Bonardel G, Soria JC, Besse B Tags: Bull Cancer Source Type: research
The Bulletin du cancer: the years before the First World War.
Abstract Three years after its founding in 1909, the Association française pour l'étude du cancer is a major scientific society developing transdisciplinary debates particularly on innovative therapeutics in cancer, such as the developing use of radium. The Association at that time assembles together all the French medical elite. Reading the Bulletin offers a clear view of the brilliant monthly debates. First World War stopped the life of the Association for four years. After this break, the set up of dedicated centers for cancer treatment was responsible for a major turn in the Association's life. ...
Source: Bulletin du Cancer - November 27, 2013 Category: Cancer & Oncology Authors: Bernaudin JF Tags: Bull Cancer Source Type: research
The issue of low doses in radiation therapy and impact on radiation-induced secondary malignancies.
Abstract Several studies have well documented that the risk of secondary neoplasms is increasing among patients having received radiation therapy as part of their primary anticancer treatment. Most frequently, radiation-induced neoplasms occur in volume exposed to high doses. However, the impact of "low" doses (
Source: Bulletin du Cancer - November 20, 2013 Category: Cancer & Oncology Authors: Chargari C, Cosset JM Tags: Bull Cancer Source Type: research
Sarcomas, example of a pathologist network organization.
We describe the network organization and report the results of the first two years of activity. These results clearly show the interest of this organization for the patients as well as for all pathologists. Moreover, data and material collect allows a better knowledge of these tumors and an improvement of the rules for their diagnostic management. PMID: 24257139 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 20, 2013 Category: Cancer & Oncology Authors: Neuville A, Coindre JM Tags: Bull Cancer Source Type: research
Dependence receptors: life or death choices.
Abstract Whereas the classic dogma postulates that transmembrane receptors remain inactive at the plasma membrane unless bound by their specific ligand, it was suggested that some receptors may actually be active not only in the presence of their ligand, but also in their absence. In this latter case, the signaling downstream of these unbound receptors leads to apoptosis. These receptors were consequently named dependence receptors, as their cell expression renders the survival of the cell dependent on the presence in the cell environment of its respective ligand. This dual function - positive in the presence...
Source: Bulletin du Cancer - November 18, 2013 Category: Cancer & Oncology Authors: Delcros JG, Mehlen P Tags: Bull Cancer Source Type: research
Malignant pleural mesothelioma: 2013 state of the art.
Abstract Malignant pleural mesothelioma (MPM) is a bad-prognosis cancer raising difficult issues according to diagnosis. Reliable histological diagnosis indeed requires large-sized pathological samples obtained by thoracoscopy, and need diagnosis certification by the MESOPATH national expert pathological committee. MPM epidemiology shows a rising incidence among females, whereas an incidence plateau has been reached for males in France. The incidence peak is still predicted for 2030 decade in UK, Australia and North America, because of the asbestosis massive use in their industry until the end of 1980 decade. Pleu...
Source: Bulletin du Cancer - November 14, 2013 Category: Cancer & Oncology Authors: Campbell K, Brosseau S, Reviron-Rabec L, Bergot E, Lechapt E, Levallet G, Zalcman G Tags: Bull Cancer Source Type: research
Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting.
cci F Abstract Breast cancer is now considered as a large collection of distinct biological entities, the management of which is increasingly personalized. Personalized medicine - defined as a medicine, which uses molecular profiles, notably genetic profiles, from patients and/or tumors to tailor therapeutic decisions - is now introduced in the management of breast cancer at any stages: screening and prevention of hereditary forms, prognostic and predictive evaluation of early breast cancer, and, more recently, novel clinical trials in advanced breast cancer, where genetic characterization of tumor tissu...
Source: Bulletin du Cancer - November 13, 2013 Category: Cancer & Oncology Authors: Gonçalves A, Moretta J, Eisinger F, Bertucci F Tags: Bull Cancer Source Type: research
Morphological imaging for response assessment in metastatic bone disease.
Abstract Response assessment with morphological imaging in metastatic bone disease is difficult. X-Ray is useful only for long bones. CT is the best imaging modality for assessment of osteolysis and osteosclerosis. MRI is the gold standard for bone marrow morphological imaging. Morphological MR imaging using basic sequences, especially T1, provides confident evaluation of the behaviour of lesions under therapy. Radiotherapy and interventional radiology may induce cortical and bone marrow changes. PMID: 24197057 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 6, 2013 Category: Cancer & Oncology Authors: Feydy A Tags: Bull Cancer Source Type: research
The surgical treatment of metastases in the appendicular skeleton.
Abstract The orthopedic surgical treatment of metastases is very important in the treatment of osteophile cancers. The surgical option is always proposed after a multidisciplinary decision. The main risk of the metastases is the pathological fracture. This risk has to be evaluated and a preventive treatment can often be performed. The surgical options are multiple: such as preventive osteosynthesis, pathological fracture treatment, reconstruction with prosthesis, carcinological excision… The choice of the treatment is support on the life expectancy and the functional risk of the metastatic bone lesion. ...
Source: Bulletin du Cancer - November 6, 2013 Category: Cancer & Oncology Authors: Szymanski C Tags: Bull Cancer Source Type: research
Histology of bone metastases (technical aspects, searching for a primary).
Abstract The histologic diagnosis of bone metastasis is often easy, based on tumor morphologic features on routine examination. The determination of the primary tumor is facilitated by ancillary techniques such as histochemical stainings and immunohistochemistry: it is possible, in about 65% of cases, with clinical correlation. Additional immunohistochemistry or molecular analyses are becoming more useful in various tumors (breast, lung, melanoma…) to give targeted therapy. From a technical point of view, bone is characterised by its difficulty to be sampled (with frequent crushing artifacts) and the necess...
Source: Bulletin du Cancer - November 5, 2013 Category: Cancer & Oncology Authors: Larousserie F, Genestie C Tags: Bull Cancer Source Type: research
Imaging of bone metastases.
Abstract Bone metastases are detected at initial diagnosis of cancer in 25% of cases and bone metastases are common in the course of a majority of cancer types. The spine and proximal long bones are the most affected sites. Knowledge of the basic radiological semiology is important to make the proper diagnosis of metastasis(s) bone(s), especially in situations in which the clinical context is not suggestive of metastases (such as cases where bone metastases are inaugural or cases of peripheral solitary metastasis). Tumor aggressiveness can be assessed at the level of the cortical bone and periosteum. Lodwick crite...
Source: Bulletin du Cancer - November 4, 2013 Category: Cancer & Oncology Authors: Amoretti N, Thariat J, Nouri Y, Foti P, Hericord O, Stolear S, Coco L, Hauger O, Huwart L, Boileau P Tags: Bull Cancer Source Type: research
Advances in radiation oncology for metastatic bone disease.
Abstract Irradiation of bone metastases primarily aims at alleviating pain, preventing fracture in the short term. The higher doses and more conformal dose distribution achievable while saving healthy tissue with new irradiation techniques have induced a paradigm shift in the management of bone metastases in a growing number of clinical situations. A search of the English and French literature was conducted using the keywords: bone metastases, radiotherapy, interventional radiology, vertebroplasty, radiofrequency, chemoembolization. Stereotactic irradiation yields pain relief rates greater than 90% in Phase I/II a...
Source: Bulletin du Cancer - October 30, 2013 Category: Cancer & Oncology Authors: Thariat J, Fric D, Kerr C, Leysalle A, Angellier G, Dejean C, Tuillier T, Bensadoun RJ, Lagrange JL Tags: Bull Cancer Source Type: research
Epidemiology and clinical features of bone metastases.
Abstract The actual improvement of epidemiologic database collection concerning bone metastases of solid tumors allows us to better understand the seriousness of this evolution, its human, social and financial burden. A renewal of interest appeared with a better screening of the asymptomatic forms and by the therapeutic advances obtained by bone resorption inhibitors. They were developed in clinical trials with a specific and original methodology evaluating their efficacy on the skeletal-related events (SRE) (pain, fracture, spinal cord compression, pathologic fracture and hypercalcemia). It is a major concern for...
Source: Bulletin du Cancer - October 29, 2013 Category: Cancer & Oncology Authors: Cvitkovic F, Mouret-Fourme E Tags: Bull Cancer Source Type: research
Multidisciplinary meetings dedicated to bone metastases: a historical perspective and rationale.
Abstract Bone metastases of solid tumors have a strong impact on patient's autonomy and vital outcome. Drugs specifically targeting bone remodeling as well as local treatment (radiotherapy, osteoplasty, surgery) make the management of bone metastasis a multidisciplinary process. Multidisciplinary teams (MDTs) dedicated to bone metastasis aim at providing the diagnosis of certainty, defining treatment indications and monitoring follow-up. The MDTs are the place for innovation in imaging and treatments of bone metastases. PMID: 24165281 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 28, 2013 Category: Cancer & Oncology Authors: Vieillard MH, Thureau S Tags: Bull Cancer Source Type: research
Waiting times for cancer care in four most frequent cancers in several French regions in 2011 and 2012.
This study was piloted by the French Cancer Institute in partnership with the National Federation of the Regional Health Observatories and was driven by the Regional Oncology Networks and the Regional Health Observatories. In 2011, 2,530 women with breast cancer and 1,945 patient with lung cancer were included in eight regions, and in 2012, 3,248 patients with colon cancer and 4,207 men with prostate cancer were included in 13 regions, two of which were overseas departments. Data were analyzed from multidisciplinary discussion reports and from medical records. The mean time intervals (± st...
Source: Bulletin du Cancer - October 24, 2013 Category: Cancer & Oncology Authors: Pourcel G, Ledesert B, Bousquet PJ, Ferrari C, Viguier J, Buzyn A Tags: Bull Cancer Source Type: research
Bone targeted therapies: new agents.
Abstract The development of bisphosphonates and anti-RANK/RANKL agents was associated with a better understanding of physiological and pathological processes of bone remodeling. New agents are now developed in this context targeting factors associated with osteoclastogenesis (TGFβ, PTHrP), with signaling pathways activated during bone remodeling (Src, Cathepsin K) or with tumor cells homing into bone (chemokines). This review aims to present the underlying rationale for these developments as well as the clinical results. The emergence of new bone targeting therapies is discussed. PMID: 24158596 [PubMed -...
Source: Bulletin du Cancer - October 24, 2013 Category: Cancer & Oncology Authors: Barth C, Massard C, Vignot S Tags: Bull Cancer Source Type: research
Inhibition of RANK Ligand to treat bone metastases.
Abstract Bone is the most common metastatic site. The skeleton is also the preferential initial metastatic site in breast and prostate carcinomas. Objective complications of bone metastases are named « skeletal-related events » (SREs) and generally include the need for radiotherapy on bone, surgery to bone, pathologic fracture and spinal cord compression. Recent phase III double-blind trials have demonstrated the superiority of denosumab to zoledronic acid for delaying the time to first SRE in patients with breast or prostate cancer and bone metastases. Non-inferiority was shown in the trial ...
Source: Bulletin du Cancer - October 24, 2013 Category: Cancer & Oncology Authors: Body JJ Tags: Bull Cancer Source Type: research
Biomarkers of bone remodelling.
Abstract Bone is a frequent site for metastases patients with advanced solid tumors. Metastatic bone disease alters bone homeostasis and biochemical markers of bone turnover are studied in patients with cancer. These markers include bone matrix synthesis and degradation products, or enzymes expressed by osteoblasts or osteoclasts. Thus, the use of these biochemical markers of bone metabolism is being evaluated in screening for development of bone metastases, in predicting risk of skeletal-related events and survival in patients with bone metastases, and in monitoring response to antiresorptive therapy. Bone marker...
Source: Bulletin du Cancer - October 24, 2013 Category: Cancer & Oncology Authors: Debiais F Tags: Bull Cancer Source Type: research
Bone targeting agents: bisphosphonates.
Abstract Malignant tumor osteolysis is a frequent complication in many cancers. It can cause skeletal-related events with alteration of quality of life and survival. Bisphosphonates play an important role in the management of this malignant osteolysis, via an inhibition of osteoclast-mediated bone resorption, and a potential direct antitumor activity. Their use constitutes an important therapeutic advance in patients with bone metastases so as to reduce or delay the appearance of these skeletal events. They are also useful for the treatment of hypercalcemia, which could arise in these patients. Their interest as a...
Source: Bulletin du Cancer - October 24, 2013 Category: Cancer & Oncology Authors: Debiais F Tags: Bull Cancer Source Type: research
Radiotherapy of bone metastases.
Abstract Sixty percent of cancer patients have or develop bone metastases during the development of their cancer. Bone metastases are the most common cause of cancer-related pain. External radiation therapy is the standard treatment of uncomplicated bone metastases, for the treatment of pain, the prevention of fracture, and for tumor control. Fractionation schedules (one session of 8 Gy or several sessions, typically 30 Gy in 10 fractions) vary in terms of efficacy with however more retreatments after a single session. The treatment of spinal cord compression is classically based on radiotherapy...
Source: Bulletin du Cancer - October 24, 2013 Category: Cancer & Oncology Authors: Leysalle A, Thariat J, Fric D, Lagrange JL Tags: Bull Cancer Source Type: research
Surgical treatment of vertebral metastases.
Abstract The multiplicity of clinical presentations and the lack of consensus explain that the treatment of spine metastasis remains controversial. Optimal treatment requires a truly multidisciplinary approach, involving oncologists, interventional radiologists, radiation oncologists, rheumatologists and spine surgeons. Recent progress in all these areas have allowed to provide safe and effective therapeutic solutions tailored to each situation. We remind, in this work, the main progress in the surgical field, specifying the role of surgery in the current therapeutic arsenal. PMID: 24158726 [PubMed - as suppl...
Source: Bulletin du Cancer - October 24, 2013 Category: Cancer & Oncology Authors: Zairi F, D'Houtaud S, Assaker R Tags: Bull Cancer Source Type: research
State of the art in nuclear imaging for the diagnosis of bone metastases.
Abstract Cancers prone to spread to bone include prostate, lung, kidney, breast and thyroid cancers. While bone scanner has been widely used in the past decades, PET-based imaging modalities are increasingly used. Current modalities of PET imaging of bone metastases include tumor and inflammatory targeting with FDG-PET, bone imaging with NaF-PET, and direct cancer-specific markers such as FDOPA-PET or PET using choline. The cancer-specific metastatic patterns and the relative prognosis conferred by osseous metastases (versus visceral metastases) may determine the need for bone scan, FDG-PET for the detection of bo...
Source: Bulletin du Cancer - October 23, 2013 Category: Cancer & Oncology Authors: Ouvrier MJ, Vignot S, Thariat J Tags: Bull Cancer Source Type: research
Pathophysiology of bone metastases and new molecular targets involved in bone remodelling.
din P Abstract Bone metastases are common complications of cancers. These skeletal lesions are usually osteolytic (excess of bone destruction), osteosclerostic (excess of bone formation) or mixed. Metastatic cancer cells residing in the bone marrow alter the functions of bone-resorbing (osteoclasts) and bone-forming (osteoblasts) cells and hijack signals coming from the bone matrix. In this review, we first described cellular and molecular mechanisms that drive cancer cells to colonize the bone marrow. We next show how cancer cells alter bone remodelling to promote the formation of osteolytic or osteosclerotic les...
Source: Bulletin du Cancer - October 22, 2013 Category: Cancer & Oncology Authors: Clézardin P Tags: Bull Cancer Source Type: research
Interventional radiology for bone metastases.
Abstract The management of bone metastases requires a multidisciplinary staff to include systemic and local treatments like radiotherapy, surgery or interventional radiology (IR). Patients are often fragile. Imaging allows safe guidance to create "mini-invasive" procedures under adequate anesthesia. Patients' selection is important. If the goal is pain relief, cementoplasty provides a very effective bone consolidation and pain control. Simple and low-risk, vertebroplasty is the technique of choice in case of lytic bone metastases with spinal fracture risk or after failure of analgesic radiotherapy. If th...
Source: Bulletin du Cancer - October 22, 2013 Category: Cancer & Oncology Authors: Iannessi A, Garnon J, Cormier E, Clarencon F, Chiras J Tags: Bull Cancer Source Type: research
Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC.
, Chibaudel B, Girard-Calais MH, Cornely A, Vintonenko N, Calais G, De Raucourt D, Lacau Saint-Guily J, Bourhis J Abstract Head and neck cancers are the fifth among the most common cancers in France. Two thirds of cases occur at an advanced stage. For advanced disease, progression-free survival, despite undeniable progress, remains below 50% at three years. The last 20 years have been marked by the necessity to identify situations where less intense surgery and/or radiotherapy and/or chemotherapy is possible without jeopardizing the prognosis, and situations where a therapeutic intensification is necessary an...
Source: Bulletin du Cancer - October 14, 2013 Category: Cancer & Oncology Authors: Thariat J, Jegoux F, Pointreau Y, Fayette J, Boisselier P, Blanchard P, Alfonsi M, Aupérin A, Bardet E, Bensadoun RJ, Garaud P, Geoffrois L, Graff P, Guigay J, Janot F, Lapeyre M, Lefebvre JL, Martin L, Racadot S, Rolland F, Sire C, Tao Y, Tuchais C, Chi Tags: Bull Cancer Source Type: research
The importance of adherence to oral therapies in the field of oncology: the example of breast cancer.
The objective of this paper is to synthesize current knowledge on adherence and persistence to hormonal therapy for BC. Available studies display significant heterogeneity due to variability in the measurements and data sources used, as well as in the timing of the measurements. Adherence and persistence estimates have recently been summarized in a meta-regression analysis. For tamoxifen, adherence ranges from 79% at one year to 65% at five years, and for Aromatase Inhibitors (AI), from 80% at one year to 72% at five years. Persistence decreases with the increasing duration of treatment: from a high of 86% of patients pers...
Source: Bulletin du Cancer - October 9, 2013 Category: Cancer & Oncology Authors: Huiart L, Bardou VJ, Giorgi R Tags: Bull Cancer Source Type: research
Molecular and therapeutic advances in Hairy cell leukemia.
Abstract Hairy cell leukemia is a rare chronic lymphoproliferative disorder. Its diagnosis remains difficult due to different variant forms and differential diagnosis that are splenic marginal zone lymphoma and b-prolymphocytic leukemia. The prognosis of this malignancy has been transformed by purine nucleoside analogs, interferon, monoclonal antibodies and recombinant immunotoxins usually used in refractory or relapsed disease. The discovery of BRAF V600E mutation has become the milestone in the disease's history since it was uniformly identified in a HCL series in 2011. This mutation, commonly identified in mela...
Source: Bulletin du Cancer - October 8, 2013 Category: Cancer & Oncology Authors: Balsat M, Cornillon J Tags: Bull Cancer Source Type: research
Vitamin D and breast cancer: physiopathology, biological and clinical implications.
Vitamin D and breast cancer: physiopathology, biological and clinical implications. Bull Cancer. 2013 Oct 8; Authors: Firmin N, Lamy PJ, Romieu G, Jacot W Abstract There is a recent increase in interest of vitamin D and breast cancer, facing the number of publications on the subject. This increase have several reasons, on the one hand, vitamin D deficiency is more and more prevalent and, on the other hand, there are new data that highlights the extra-bone effects of vitamin D, especially in breast cancer, the vitamin D is involved in the breast cancer risk factor, the prognosis, an...
Source: Bulletin du Cancer - October 8, 2013 Category: Cancer & Oncology Authors: Firmin N, Lamy PJ, Romieu G, Jacot W Tags: Bull Cancer Source Type: research
Is the surgeon still the main prognosis factor?
te; A Abstract Assessment of surgeon's influence on the results of cancer surgery is complex. Investigation field is extremely large and should differentiate surgeon's impact from the one of surgery. This can result in major differences in the rate of postoperative complications and deaths, in the indication and use of technically difficult surgeries, and also in long-term results. The surgeon's impact is correlated with his activity volume for each type of major procedures and is independent from hospital activity volume. It persists independently of major progresses in hospital organization and process standardi...
Source: Bulletin du Cancer - October 8, 2013 Category: Cancer & Oncology Authors: Rivoire M, Dupré A Tags: Bull Cancer Source Type: research
Comparative cost analysis of molecular biology methods in the diagnosis of sarcomas.
our F Abstract Sarcomas represent a complex and heterogeneous group of rare malignant tumors and their correct diagnosis is often difficult. Recent molecular biological techniques have been of great diagnostic use and there is a need to assess the cost of these procedures in routine clinical practice. Using prospective and observational data from eight molecular biology laboratories in France, we used "microcosting" method to assess the cost of molecular biological techniques in the diagnosis of five types of sarcoma. The mean cost of fluorescence in situ hybridization (FISH) was 318 € (273-393...
Source: Bulletin du Cancer - October 4, 2013 Category: Cancer & Oncology Authors: Baffert S, Italiano A, Pierron G, Traoré MA, Rapp J, Escande F, Ghnassia JP, Terrier P, Voegeli AC, Ranchere-Vince D, Coindre JM, Pedeutour F Tags: Bull Cancer Source Type: research
The announcement of the diagnosis of cancer: point of view of the general practitioner.
ois C Abstract The announcement of the diagnosis of cancer is difficult for doctors and patients alike. The main objective is the study of announcement's techniques used by physicians to send their patients in cancer centers. The second objective is to analyze encountered difficulties and experience of the announcement of the diagnosis. The final objective would be to provide practical ideas for GPs for a better communication with their patients in this announcement. We have conducted a qualitative study by interviewing fifteen GPs. The fifteen semi-structured interviews have been recorded and transcribed verbatim...
Source: Bulletin du Cancer - October 4, 2013 Category: Cancer & Oncology Authors: Ferraton-Rollin M, Magné N, Gonthier R, Merrouche Y, Bois C Tags: Bull Cancer Source Type: research
Advanced directives: nurses' and physicians' representations in 2012.
The objective of this study was to investigate nurses' and physicians' representations towards AD. A questionnaire had been sent to hospitals, public health facilities and liberal practitioners during February 2012. We collected responses from 42/251 physicians (17 %) and 80/198 nurses (40 %). Sixty percent of participants reported that they were not familiar with the legislative framework for AD. For physicians, main barriers were patient cognitive impairment (P = 0.004) and lack of information on the clinical situation (P = 0.004). For nurses, difficulties were toward end o...
Source: Bulletin du Cancer - September 30, 2013 Category: Cancer & Oncology Authors: Ledoux M, Rhondali W, Monnin L, Thollet C, Gabon P, Filbet M Tags: Bull Cancer Source Type: research
Treatment of primary thyroid lymphomas.
Abstract Primary lymphomas of the thyroid (LPT) are a rare entity. LPT represent between 5 and 15% of all thyroid neoplasms. Cytology has limited value; biopsy should be recommended. The differential diagnosis of thyroid carcinoma is differentiated forms indolent or aggressive forms for anaplastic and high grade that may occur by a mass rapidly progressive and compressive. LPT represent a histologically and clinically heterogeneous disease. The most common forms are high-grade LPT (DBLCL) of diffuse large cell type or mucosa-associated lymphoid tissue (MALT). DBLCL receive chemotherapy. The benefit of irradiation ...
Source: Bulletin du Cancer - September 30, 2013 Category: Cancer & Oncology Authors: Sun XS, Bay JO, Marcy PY, Hammoud Y, Lacout A, Michels JJ, Guevara N, Thariat J Tags: Bull Cancer Source Type: research
Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer.
in JL Abstract Breast cancer is the most common cancer among women with more than 53,000 new cases every year in France. The PI3K/AKT pathway is one of the major pathways involved in mammary tumorigenesis. The first effector of this pathway downstream Human Epidermal growth factor Receptor (HER receptors) is the enzyme phosphatidyl-inositol-3-kinase (PI3K). Some mutations in the gene encoding for the catalytic subunit of this enzyme, the PIK3CA gene, plays an important role, especially in the resistance to targeted therapies used clinically during the last decade. Indeed, the presence of alterations, an overexpres...
Source: Bulletin du Cancer - September 30, 2013 Category: Cancer & Oncology Authors: Harlé A, Lion M, Lozano N, Merlin JL Tags: Bull Cancer Source Type: research
Impact of depressive disorders on adherence to oral anti-cancer treatment.
In this study, we use the examples of the imatinib treatment against chronic lymphocytic leukemia and the tamoxifene treatment against breast cancer to assess the negative consequences of the non-adherence to therapy in terms of medical outcome and health care cost. One of the main causes of non-adherence to these oral cancer treatments is depression. Surprisingly, this aspect is still relatively unknown to oncologists, while depression has been taken into account for the treatment of other chronic diseases (e.g. diabetes…). We therefore propose that cancer patients should be screened for depression throughout their...
Source: Bulletin du Cancer - September 25, 2013 Category: Cancer & Oncology Authors: Chabrier M, Bezy O, Mouret MA, Bay JO, Jalenques I Tags: Bull Cancer Source Type: research
Regorafenib approved in Metastatic Colorectal cancer.
This study showed an improved overall survival, with régorafénib versus placebo (6.4 months vs 4 months; HR = 0.774, IC à 95%, 0.64 à 0.94; p = 0,005 2). Reported grade 3-4 adverse events with regorafenib were hand-foot syndrome (17%), asthenia (10%), diarrhea (7%), hypertension (7%), rash and desquamation (6%). PMID: 24047557 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 18, 2013 Category: Cancer & Oncology Authors: André T, Dumont SN Tags: Bull Cancer Source Type: research
Aflibercept (Zaltrap(®)) approved in Metastatic Colorectal Cancer.
This study showed an improved overall survival, with the combination of aflibercept and FOLFIRI versus FOLFIRI + placebo (13.5 months vs 12.06 months ; HR = 0,817, IC à 95 %, 0,714 à 0,935 ; p = 0,003 2). Adverse effects reported with aflibercept combined with FOLFIRI included the specific anti-vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities. Aflibercept is the second anti-angiogenic agent after bevacizumab with a FDA and a EMEA approval for patients with metastatic...
Source: Bulletin du Cancer - September 16, 2013 Category: Cancer & Oncology Authors: André T, Chibaudel B Tags: Bull Cancer Source Type: research
Uterine leiomyosarcoma: epidemiology, pathology, biology, diagnosis, prognosis and treatment.
ier P Abstract Uterine leiomyosarcoma is a rare disease with a poor prognosis. The rarity of this tumor needs a specialized management in tertiary reference centers in order to provide patients with optimal diagnostic, prognostic and therapeutic care. The pathological diagnosis relies on the presence of three characteristics in proliferating smooth muscle cells: necrosis, cytologic atypia and mitosis. Despite progress in the knowledge of the biology of these tumors, no oncogenic driver has been found. Prognosis depends mainly on the age of the patient, race, FIGO stage, mitotic index and hormonal receptor expressi...
Source: Bulletin du Cancer - September 4, 2013 Category: Cancer & Oncology Authors: Hadoux J, Morice P, Lhommé C, Duvillard P, Balleyguier C, Haie-Meder C, Gouy S, Uzan C, Mazeron R, Tazi Y, Leary A, Duffaud F, Pautier P Tags: Bull Cancer Source Type: research
Evolving strategies over time for treatment of breast cancer.
te; H Abstract The natural history of breast diseases has changed overtime and successive therapeutic strategies have been adapted accordingly. Recently, biological findings on geno- and phenotypic characteristics of tumor cells offer new basis for the development of treatments that target homogenous and various subtypes of breast cancer. Unfortunately, traditional clinical research tools are not in phase with rapid changes in both biological knowledge of the disease and new targeted agents. New methodological approaches are urgently needed to validate such changes and improvements in prognosis. PMID: 2400461...
Source: Bulletin du Cancer - September 4, 2013 Category: Cancer & Oncology Authors: Roché H Tags: Bull Cancer Source Type: research
Ruxolitinib prescription in myelofibrosis.
ay JO Abstract Ruxolitinib is a JAK/STAT inhibitor, which has demonstrated clinical benefits in patients with intermediate-2 and high-risk myelofibrosis. Moreover, first results of recent clinical trials show a trend to better overall survival with ruxolitinib, which allows to hope that we will soon be able to change the natural evolution of this poor outcome disease. With such results, ruxolitinib quickly obtained the Food and Drug Administration (FDA) approval in the United States of America. In France, ruxolitinib is now available, allowing its administration to symptomatic myelofibrosis patients. PMI...
Source: Bulletin du Cancer - August 28, 2013 Category: Cancer & Oncology Authors: Lemal R, Robin M, Ravinet A, Cacheux V, Guièze R, Bay JO Tags: Bull Cancer Source Type: research
Use of midazolam in hospitalized patients: analysis of medical practice.
Abstract To evaluate the prevalence and the characteristics of use of midazolam among hospitalized patients and to analyze physicians' representation of this medicine. We conducted a retrospective study between 1st May and 22nd May 2011 in Grenoble University Hospital in France. All patients receiving midazolam during the study period were included, excepted if the prescription was performed in intensive care units, operating rooms or in pediatric units. Physicians from the different units were asked about the characteristics of patients receiving midazolam and about their practice concerning the us...
Source: Bulletin du Cancer - August 28, 2013 Category: Cancer & Oncology Authors: Giroud M, Sellier E, Laval G Tags: Bull Cancer Source Type: research
Role of the surgical pathologist for tissue management in oncology.
Abstract Currently, the increasing number of ancillary methods to be performed from tumoral tissues in a pathology laboratory determines the necessity to have an optimal strategy for tissue management. The size of tissue samples dedicated for a pathological examination becomes smaller and smaller, as the diagnosis can be made with non or less invasive methods. However, the samples should also allow to provide the prognosis as well as to realise biological molecular testing in order to found a genomic alteration. Thus, it is critical to think about how to share and to pool the different expertises and abilities in ...
Source: Bulletin du Cancer - August 28, 2013 Category: Cancer & Oncology Authors: Long E, Ilie M, Hofman V, Lassalle S, Butori C, Alsubaie S, Hofman P Tags: Bull Cancer Source Type: research
Small HER2-positive breast cancer: which prognosis and which adjuvant treatment?
no JP Abstract Incidence of centimetric or infracentimetric node negative (pT1a-b, N0) breast cancer is increasing due to screening procedures. Although considered as having an overall favorable prognosis, several retrospective studies have suggested a higher risk of relapse when HER2 is overexpressed. Since randomized studies evaluating trastuzumab in the adjuvant setting did not include T1a-bN0, there is no level I evidence supporting the administration of a trastuzumab-based post-operative chemotherapy in these cases. However, some recent retrospective data suggest a benefit for such a strategy and current guid...
Source: Bulletin du Cancer - July 31, 2013 Category: Cancer & Oncology Authors: Gonçalves A, Vassilakopoulou M, Spano JP Tags: Bull Cancer Source Type: research
Glutamate and malignant gliomas, from epilepsia to biological aggressiveness: therapeutic implications.
Abstract In this review article, we describe the unrecognized roles of glutamate and glutamate receptors in malignant glioma biology. The neurotransmitter glutamate released from malignant glioma cells in the extracellular matrix is responsible for seizure induction and at higher concentration neuronal cell death. This neuronal cell death will create vacated place for tumor growth. Glutamate also stimulates the growth and the migration of glial tumor cells by means of the activation of glutamate receptors on glioma cells in a paracrine and autocrine manner. The multitude of effects of glutamate in glioma biology s...
Source: Bulletin du Cancer - July 24, 2013 Category: Cancer & Oncology Authors: Blecic S, Rynkowski M, De Witte O, Lefranc F Tags: Bull Cancer Source Type: research